171 related articles for article (PubMed ID: 16000955)
1. Vaccination of cytotoxic T lymphocyte-directed peptides elicited and spread humoral and Th1-type immune responses to prostate-specific antigen protein in a prostate cancer patient.
Harada M; Matsueda S; Yao A; Noguchi M; Itoh K
J Immunother; 2005; 28(4):368-75. PubMed ID: 16000955
[TBL] [Abstract][Full Text] [Related]
2. CD8-based T cell vaccination and CD4 T cell responses in prostate cancer.
Alexander RB
J Immunother; 2005; 28(4):295-6. PubMed ID: 16000946
[No Abstract] [Full Text] [Related]
3. Identification of HLA-DRB1*1501-restricted T-cell epitopes from prostate-specific antigen.
Klyushnenkova EN; Link J; Oberle WT; Kodak J; Rich C; Vandenbark AA; Alexander RB
Clin Cancer Res; 2005 Apr; 11(8):2853-61. PubMed ID: 15837732
[TBL] [Abstract][Full Text] [Related]
4. In vivo evidence that peptide vaccination can induce HLA-DR-restricted CD4+ T cells reactive to a class I tumor peptide.
Harada M; Gohara R; Matsueda S; Muto A; Oda T; Iwamoto Y; Itoh K
J Immunol; 2004 Feb; 172(4):2659-67. PubMed ID: 14764741
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients.
Harada M; Kobayashi K; Matsueda S; Nakagawa M; Noguchi M; Itoh K
Prostate; 2003 Oct; 57(2):152-9. PubMed ID: 12949939
[TBL] [Abstract][Full Text] [Related]
6. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
Noguchi M; Kobayashi K; Suetsugu N; Tomiyasu K; Suekane S; Yamada A; Itoh K; Noda S
Prostate; 2003 Sep; 57(1):80-92. PubMed ID: 12886526
[TBL] [Abstract][Full Text] [Related]
7. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide.
Correale P; Walmsley K; Zaremba S; Zhu M; Schlom J; Tsang KY
J Immunol; 1998 Sep; 161(6):3186-94. PubMed ID: 9743387
[TBL] [Abstract][Full Text] [Related]
8. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
9. Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer.
McNeel DG; Nguyen LD; Ellis WJ; Higano CS; Lange PH; Disis ML
Prostate; 2001 May; 47(3):222-9. PubMed ID: 11351352
[TBL] [Abstract][Full Text] [Related]
10. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-PatiƱo J; Andersen RS; Pisa P
Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
[TBL] [Abstract][Full Text] [Related]
11. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation.
Chakraborty NG; Stevens RL; Mehrotra S; Laska E; Taxel P; Sporn JR; Schauer P; Albertsen PC
Cancer Immunol Immunother; 2003 Aug; 52(8):497-505. PubMed ID: 12783216
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer.
Noguchi M; Itoh K; Suekane S; Yao A; Suetsugu N; Katagiri K; Yamada A; Yamana H; Noda S
Cancer Sci; 2004 Jan; 95(1):77-84. PubMed ID: 14720331
[TBL] [Abstract][Full Text] [Related]
13. CD4 and CD8 T-lymphocyte recognition of prostate specific antigen in granulomatous prostatitis.
Klyushnenkova EN; Ponniah S; Rodriguez A; Kodak J; Mann DL; Langerman A; Nishimura MI; Alexander RB
J Immunother; 2004; 27(2):136-46. PubMed ID: 14770085
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
[TBL] [Abstract][Full Text] [Related]
15. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen.
Correale P; Walmsley K; Nieroda C; Zaremba S; Zhu M; Schlom J; Tsang KY
J Natl Cancer Inst; 1997 Feb; 89(4):293-300. PubMed ID: 9048833
[TBL] [Abstract][Full Text] [Related]
16. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide.
Perambakam S; Hallmeyer S; Reddy S; Mahmud N; Bressler L; DeChristopher P; Mahmud D; Nunez R; Sosman JA; Peace DJ
Cancer Immunol Immunother; 2006 Sep; 55(9):1033-42. PubMed ID: 16283303
[TBL] [Abstract][Full Text] [Related]
17. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
[TBL] [Abstract][Full Text] [Related]
18. Differential CTLs specific for prostate-specific antigen in healthy donors and patients with prostate cancer.
Elkord E; Williams PE; Kynaston H; Rowbottom AW
Int Immunol; 2005 Oct; 17(10):1315-25. PubMed ID: 16141246
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment.
Noguchi M; Mine T; Yamada A; Obata Y; Yoshida K; Mizoguchi J; Harada M; Suekane S; Itoh K; Matsuoka K
Oncol Res; 2007; 16(7):341-9. PubMed ID: 17518272
[TBL] [Abstract][Full Text] [Related]
20. CD4 T-Cell-mediated immune response to prostatic proteins in HLA-DRB1*1503 transgenic mice and identification of a novel HLA-DRB1*1503-restricted T-cell epitope from human prostatic acid phosphatase.
Klyushnenkova EN; Alexander RB
Prostate; 2011 May; 71(6):561-6. PubMed ID: 20886538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]